The orthodox group of antipsychotic drugs, used for almost more than half era to treat a wide range of psychiatric ailments are now being swapped in clinical as well as medical relates by contemporary ‘atypicalantipsychotis’, which embraces risperidone, aripiprazole, olanzapine clozapine, ziprasidone and others. As a category, the new xenobiotics have been uplifted as being widely superior in clinical benefits, but the indication for this is quite challenging. In the present expository review, the therapeutic benefits, pharmacologic aspects, untoward effects, tolerability and process and product cost efficiency of the current agents are taken into consideration in contrast to the existing antipsychotics. Due to the stereotypically negligible differences between agents of the two eras in terms of the above mentioned clinical aspects and moreover because of the mounting concerns about possible opposing effects and chronic health penalties of some of the modern antipsychotic drugs, it is rational to ponder both older as well as newer agents for clinical usage and moreover it is also vital to notify patients about the considerable risks, benefits and costs of explicit selections of the same

Keywords : Atypical, antipsychotics, xenobiotics, untoward effect, tolerability